Cargando…
Dysregulation of immunity in COVID-19 and SLE
The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417079/ https://www.ncbi.nlm.nih.gov/pubmed/36028612 http://dx.doi.org/10.1007/s10787-022-01047-2 |
_version_ | 1784776625959731200 |
---|---|
author | Hejazian, Seyyed Sina Hejazian, Seyyedeh Mina Farnood, Farahnoosh Abedi Azar, Sima |
author_facet | Hejazian, Seyyed Sina Hejazian, Seyyedeh Mina Farnood, Farahnoosh Abedi Azar, Sima |
author_sort | Hejazian, Seyyed Sina |
collection | PubMed |
description | The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk of developing certain diseases. Systemic lupus erythematosus (SLE), an autoimmune disease in the human body, develops an immune response against its own components. In these patients, due to underlying immune system disorders and receipt of immunosuppressive drugs, the susceptibility to infections is higher than in the general population and is the single largest cause of mortality in this group. COVID-19 infection, which first appeared in late 2019, has caused several concerns in patients with SLE. However, there is no strong proof of additional risk of developing COVID-19 in patients with SLE, and in some cases, studies have shown less severity of the disease in these individuals. This review paper discusses the immune disorders in SLE and COVID-19. |
format | Online Article Text |
id | pubmed-9417079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-94170792022-08-30 Dysregulation of immunity in COVID-19 and SLE Hejazian, Seyyed Sina Hejazian, Seyyedeh Mina Farnood, Farahnoosh Abedi Azar, Sima Inflammopharmacology Review The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk of developing certain diseases. Systemic lupus erythematosus (SLE), an autoimmune disease in the human body, develops an immune response against its own components. In these patients, due to underlying immune system disorders and receipt of immunosuppressive drugs, the susceptibility to infections is higher than in the general population and is the single largest cause of mortality in this group. COVID-19 infection, which first appeared in late 2019, has caused several concerns in patients with SLE. However, there is no strong proof of additional risk of developing COVID-19 in patients with SLE, and in some cases, studies have shown less severity of the disease in these individuals. This review paper discusses the immune disorders in SLE and COVID-19. Springer International Publishing 2022-08-26 2022 /pmc/articles/PMC9417079/ /pubmed/36028612 http://dx.doi.org/10.1007/s10787-022-01047-2 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Hejazian, Seyyed Sina Hejazian, Seyyedeh Mina Farnood, Farahnoosh Abedi Azar, Sima Dysregulation of immunity in COVID-19 and SLE |
title | Dysregulation of immunity in COVID-19 and SLE |
title_full | Dysregulation of immunity in COVID-19 and SLE |
title_fullStr | Dysregulation of immunity in COVID-19 and SLE |
title_full_unstemmed | Dysregulation of immunity in COVID-19 and SLE |
title_short | Dysregulation of immunity in COVID-19 and SLE |
title_sort | dysregulation of immunity in covid-19 and sle |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417079/ https://www.ncbi.nlm.nih.gov/pubmed/36028612 http://dx.doi.org/10.1007/s10787-022-01047-2 |
work_keys_str_mv | AT hejazianseyyedsina dysregulationofimmunityincovid19andsle AT hejazianseyyedehmina dysregulationofimmunityincovid19andsle AT farnoodfarahnoosh dysregulationofimmunityincovid19andsle AT abediazarsima dysregulationofimmunityincovid19andsle |